Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Quest Diagnostics and Waters Corporation announced a collaboration to broaden at-home cervical cancer screening using the FDA-cleared Onclarity Self-Collection Kit, rolled out across Quest's clinician, health plan, and consumer channels beginning in 2027. Samples collected at home will be processed in Quest labs on the automated BD COR System, with the BD Onclarity HPV Assay providing extended genotyping that supports all ASCCP risk-based management guidelines. For Quest, the deal leverages its network of roughly 2,000 patient service centers and questhealth.com consumer channel to reach the more than 24 million un- and under-screened U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.